Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
33.56
+0.09 (0.27%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $44.75M in the quarter ending June 30, 2026, with 259.25% growth. This brings the company's revenue in the last twelve months to $98.34M, up 140.58% year-over-year. In the year 2025, Agios Pharmaceuticals had annual revenue of $54.03M with 48.03% growth.
Revenue (ttm)
$98.34M
Revenue Growth
+140.58%
P/S Ratio
20.37
Revenue / Employee
$182,107
Employees
540
Market Cap
2.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.03M | 17.53M | 48.03% |
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Aurinia Pharmaceuticals | 311.51M |
| Septerna | 98.88M |
| Mesoblast | 65.38M |
| Stoke Therapeutics | 27.59M |
| Generate Biomedicines | 26.48M |
| Taysha Gene Therapies | 5.49M |
| Zenas BioPharma | 1.00M |
AGIO News
- 16 days ago - Agios Pharmaceuticals price target raised to $52 from $46 at Citi - TheFly
- 17 days ago - Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright - TheFly
- 17 days ago - Agios Pharmaceuticals Transcript: Transcript - Transcripts
- 17 days ago - Agios Pharmaceuticals Quarterly report - Filings
- 17 days ago - Agios Pharmaceuticals Slides - Filings
- 17 days ago - Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66) - TheFly
- 17 days ago - Agios Pharmaceuticals Earnings release - Filings
- 17 days ago - Agios Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire